At $75 a share, Utah Medical Products (UTMD) amends its offer to buy back stock.
Utah Medical Products, Inc. (UTMD) has amended its tender offer to repurchase up to 650,000 shares of its common stock at $75.00 per share. The offer is subject to terms outlined in the Offer to Purchase dated September 24, 2026. Chairman and CEO Kevin L. Cornwell directly owns 188,472 shares, representing 5.9% of the company's outstanding stock.
Utah Medical Products, Inc. Commences Tender Offer
Utah Medical Products, Inc. has announced the commencement of a tender offer to repurchase up to 200,000 shares of its common stock at a price of $80.00 per share. The offer is scheduled to expire on October 27, 2026, unless extended. Shareholders can tender all, some, or none of their shares.
Utah Medical Products, Inc. Clarifies Tender Offer Expiration Date
Utah Medical Products, Inc. (UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The company issued a clarification regarding the expiration date of this tender offer, stating that it is scheduled to expire at 5:00 p.m. New York City time, on October 7, 2026, which is a Wednesday, correcting previous announcements that incorrectly stated the date as a Tuesday. UTMD expressed regret for any confusion caused by the error.
Utah Medical Products, Inc. Clarifies Tender Offer Expiration Date
Utah Medical Products, Inc. (UTMD) has issued a clarification regarding the expiration date of its tender offer to purchase up to 650,000 shares of its common stock at $75.00 per share. The company stated that the offer is scheduled to expire on October 7 at 5:00 p.m. New York City time, correcting previous announcements that incorrectly identified October 7 as a Tuesday instead of a Wednesday. UTMD expressed regret for any confusion caused by the error.
A 17% premium to the 12-month average closing price: Utah Medical Products (UTMD) offers to buy shares.
Utah Medical Products, Inc. (UTMD) has announced a tender offer to purchase up to 650,000 shares of its common stock at $75.00 per share, representing a 17% premium over the last twelve months' average closing price. Despite a recent decline in sales and net profits, the company's board approved the offer to provide liquidity for shareholders, though it makes no recommendation on tendering shares. CEO Kevin Cornwell believes the shares are currently undervalued, suggesting a fair trading range of $90 per share based on industry valuation multiples.
Utah Medical offers to buy back shares at $75 premium By Investing.com
Utah Medical Products Inc. (NASDAQ:UTMD) has announced a tender offer to repurchase up to 650,000 shares of its common stock at $75.00 per share, representing a significant premium over recent trading prices. The company's board did not make a recommendation on tendering shares, and the offer aims to provide liquidity for shareholders. This buyback comes despite a reported 12% drop in sales and a 13% decline in net profits for the first half of 2026 compared to the previous year, with CEO Kevin Cornwell stating his belief that the shares are currently undervalued even at the offer price.
Utah Medical Products, Inc. Commences Tender Offer
Utah Medical Products, Inc. (UTMD) has announced a tender offer to purchase up to 650,000 shares of its common stock at $75.00 per share, representing a significant premium over recent trading prices. The company's CEO believes UTMD shares are undervalued, and the board sees this offer as a demonstration of confidence in the business, aiming to enhance shareholder value for those who retain their shares. The offer is set to expire on October 7, 2026, unless extended.
Wednesday, not Tuesday, is when Utah Medical Products (UTMD) expects its offer to buy shares to end.
Utah Medical Products (UTMD) is offering to buy back up to 650,000 shares of its common stock at $75.00 per share. The tender offer is scheduled to expire at 5:00 p.m. New York City time on October 7. The company clarified that October 7 falls on a Wednesday, correcting earlier announcements that incorrectly stated it as a Tuesday.
Utah Medical Products, Inc. Clarifies Tender Offer Expiration Date
Utah Medical Products, Inc. (Nasdaq:UTMD) announced an offer to purchase up to 650,000 shares of its common stock at $75.00 per share. The company clarified that the tender offer is scheduled to expire at 4:00 p.m. New York City time on October 7, 2026, which is a Wednesday, correcting previous announcements that incorrectly stated the date as a Tuesday. Utah Medical Products expressed regret for any confusion caused by the error.
A $75-a-share offer is scheduled to expire Wednesday, Oct. 7—not Tuesday.
Utah Medical Products (UTMD) has issued a correction regarding the expiration date of its tender offer. The offer, which is for up to 650,000 common shares at $75.00 per share, is now confirmed to expire on Wednesday, October 7, at 5:00 p.m. New York City time, rather than Tuesday as previously stated in some announcements. The company expressed regret for any confusion caused by the error.
Utah Medical Products, Inc. (UTMD) Clarifies Tender Offer Expiry
Utah Medical Products, Inc. (UTMD) has clarified the expiration time for its tender offer to buy back up to 650,000 shares at $75.00 per share. The offer is now set to expire at 5:00 p.m. ET on October 7, unless extended, correcting previous notices that misdated October 7. This tender offer is part of the company's capital return strategy, and its success hinges on participation rates.
Utah Medical Products, Inc. Clarifies Tender Offer Expiration Date
Utah Medical Products, Inc. (Nasdaq:UTMD) has clarified that the expiration date for its tender offer to purchase up to 650,000 shares of its common stock at $75.00 per share is October 7, 2026, which is a Wednesday. The company corrected previous announcements that incorrectly stated October 7 as a Tuesday, expressing regret for any confusion caused. Details of the offer are available in the SEC Form TO Offer to Purchase.
Utah Medical Products, Inc. Commences Tender Offer
Utah Medical Products, Inc. (UTMD) has initiated a tender offer to repurchase up to 650,000 shares of its common stock at $75.00 per share, representing a premium over recent trading prices. The company's CEO believes the stock is undervalued, and the Board of Directors supports the offer as a demonstration of confidence in the company's future despite a recent decline in sales and net profits. The offer is set to expire on October 7, 2026.
Utah Medical offers to buy back shares at $75 premium By Investing.com
Utah Medical Products Inc. (NASDAQ:UTMD) has announced a tender offer to repurchase up to 650,000 shares of its common stock at $75.00 per share, a premium over recent trading prices. The company's CEO believes the shares are currently undervalued, despite a recent decline in sales and net profits for the first half of 2026 compared to the previous year. The offer aims to provide liquidity for stockholders wishing to sell their shares.
Utah Medical Products stock reports a USD 75.00 tender offer
Utah Medical Products (UTMD) is offering a tender offer of $75.00 per share for up to 650,000 shares, representing 20% of its outstanding stock, with a deadline of October 7, 2026. This offer comes despite a 14.3% decline in Q2 2026 sales and an 11.9% decrease in net income, though the company maintained a 31.1% operating margin. The stock's current market price of $74.75 is just $0.25 below the tender offer price, and the company's market capitalization stands at $238.006 million.
Utah Medical Products, Inc. (UTMD) Starts Tender Offer at $75 for Up to 650K Shares
Utah Medical Products, Inc. (UTMD) has initiated a tender offer to acquire up to 650,000 shares at $75.00 per share, a price representing a premium over its 12- and 24-month average closing prices. The offer, which expires on October 7, aims to reduce float and potentially boost EPS, following a period of decreased sales and profits in the first half of 2026. This move is seen as a mid-cycle capital allocation strategy, with a successful uptake potentially acting as a re-rating catalyst for the company.
At $75 a share, Utah Medical Products (UTMD) offers to buy back its stock.
Utah Medical Products, Inc. (UTMD) has initiated an issuer tender offer to repurchase up to 650,000 shares of its common stock at a price of $75.00 per share. As of September 14, 2026, there were 3,173,818 shares outstanding, and executive officers and directors collectively owned 7.9% of the shares. This tender offer is detailed in a Schedule TO filing with the SEC, outlining the terms, purpose, and impact on the company and its shareholders.
Utah Medical Products, Inc. announces an Equity Buyback for 650,000 shares, representing 20.48% for $48.75 million.
Utah Medical Products, Inc. (NasdaqGS:UTMD) has announced a share repurchase program. The company plans to buy back up to 650,000 shares, which is 20.48% of its issued share capital, for a total of $48.75 million at a price of $75 per share. This program, valid until October 7, 2026, aims to provide liquidity for stockholders and will be funded from the company's available cash.
Utah Medical Products stock trades around its ex-dividend date as investors eye recent earnings
Utah Medical Products (UTMD) stock is trading near its recent range, with investors focusing on its latest earnings and dividend cycle. The company reported higher revenue and net income for the most recent quarter compared to the previous year. A dividend of USD 0.31 per share was declared, with an ex-dividend date of September 17, 2026, and a payable date of October 5, 2026.
Utah Medical Products (UTMD) plans cash tender for about 20% of its stock at a premium
Utah Medical Products (UTMD) announced an issuer self-tender offer to repurchase up to 650,000 shares of its common stock, representing about 20% of outstanding shares, at a fixed price of $75.00 per share. This price offers a significant premium over recent trading averages, with the company aiming to enhance value for continuing stockholders through anti-dilution. The offer is expected to commence on September 22, 2026, and will be funded from the company's excess cash, though the Board makes no recommendation to shareholders regarding tendering their shares.
Utah Medical Products launches tender offer at $75 per share
Utah Medical Products Inc. (NASDAQ:UTMD) has announced a tender offer to repurchase up to 650,000 shares at $75.00 per share, representing approximately 20% of its outstanding shares. This offer is at a premium of 17% above the average daily closing price over the last year and aims to enhance the value for continuing stockholders while providing an exit opportunity for those dissatisfied with the current share price. The tender offer is not conditioned on a minimum number of shares and is set to expire on October 7.
Utah Medical Products, Inc. (NASDAQ:UTMD) Self-Tenders Up To 20% At $75
Utah Medical Products, Inc. (NASDAQ:UTMD) has announced a self-tender offer to repurchase up to 650,000 shares, representing approximately 20% of its outstanding shares, at a price of $75 per share. The offer begins on September 22 and will last for about 15 business days, prioritizing odd-lot holders. This move suggests management believes the stock is undervalued and aims to return capital to shareholders.
Utah Medical Products Plans $75 Tender for 20% Shares | UTMD Stock News
Utah Medical Products (UTMD) is initiating a cash tender offer to repurchase up to 650,000 shares, approximately 20% of its outstanding stock, at $75.00 per share. This price represents a significant premium over recent trading averages, 17% above the 12-month average and 21% above the two-year average. The offer, commencing around September 22, 2026, is designed to be anti-dilutive, enhancing shareholder value for continuing stockholders, and offers an exit opportunity for those seeking to sell at a premium.
Understanding the Setup: (UTMD) and Scalable Risk
This article analyzes Utah Medical Products Inc. (NASDAQ: UTMD), highlighting weak near-term sentiment but long-term strength. It outlines an exceptional 24.4:1 risk-reward short setup and provides institutional trading strategies for different risk profiles, including position, momentum, and risk hedging strategies. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Femcare Ltd Acquires Orion Medical Supplies Ltd in the UK
Femcare Ltd, a subsidiary of Utah Medical Products, Inc., has acquired Orion Medical Supplies Ltd, a UK-based distributor of Harm Reduction medical devices. This acquisition, valued at £3.6 million, aims to generate an additional $6 million in annual sales for UTMD and leverage existing Femcare infrastructure to dilute overhead expenses. The move is expected to expand the reach of Harm Reduction products primarily in the UK and Europe.
Utah Medical’s Femcare unit acquires UK harm reduction supplier
Utah Medical Products Inc. (NASDAQ:UTMD) announced that its subsidiary Femcare Ltd. has acquired Orion Medical Supplies Ltd., a UK-based supplier of harm reduction medical devices, for £3.6 million. This acquisition is expected to add approximately $6 million to Utah Medical’s annual sales and leverage Femcare's existing infrastructure to reduce overhead expenses. The move expands Utah Medical's presence in the specialized harm reduction market within the UK and Europe.
Rice Hall James & Associates LLC Invests $4.92 Million in Utah Medical Products, Inc. $UTMD
Rice Hall James & Associates LLC has acquired a new stake in Utah Medical Products, Inc. (NASDAQ:UTMD) by purchasing 71,363 shares valued at approximately $4.92 million, representing about 2.24% of the company. Other institutional investors have also adjusted their holdings, with 69.60% of the stock owned by hedge funds and institutions. Analysts currently hold a consensus "Hold" rating for UTMD, which recently reported quarterly earnings of $0.84 per share and declared a quarterly dividend of $0.31 per share.
Utah Medical Products (UTMD) sees 2026 sales drop but builds $87.5M cash
Utah Medical Products (UTMD) reported a significant sales decline in Q2 and 1H 2026, primarily due to the loss of two major customers and slower-than-expected new product sales. Despite this, the company maintained strong profitability margins and boasts a robust balance sheet with $87.5 million in cash and investments and no debt. Management has revised its full-year 2026 revenue forecast to a 10-13% decline but continues its strategy of capital returns through dividends and share repurchases while seeking new growth opportunities.
Brandes Investment Partners reports 14.9% Utah Medical Products (UTMD) stake
Brandes Investment Partners has filed an amended Schedule 13G, disclosing a 14.92% passive ownership stake in Utah Medical Products Inc., totaling 475,158 common shares. These shares are held across mutual funds and other accounts advised by Brandes, with the Brandes Small Cap Value Fund alone holding 6.87% of the class. The filing indicates shared voting power over 435,111 shares and shared dispositive power over all 475,158 shares, with no sole control reported.
Utah Medical Products (NASDAQ:UTMD) Shares Pass Above 200 Day Moving Average - Time to Sell?
Utah Medical Products (NASDAQ:UTMD) shares have risen above their 200-day moving average, reaching $72.37 against an average of $66.51. The company reported quarterly earnings of $0.84 per share on $8.53 million in revenue and declared a $0.31 quarterly dividend, equivalent to a 1.7% annual yield. Analyst sentiment remains neutral, with a consensus "Hold" rating, despite a recent upgrade from Weiss Ratings.
Renaissance Technologies (UTMD) discloses 5.52% ownership in Utah Medical Products
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a beneficial ownership of 175,814 shares, or 5.52%, in Utah Medical Products Inc. as of June 30, 2026. Both entities hold sole voting and dispositive power over these shares. The filing, a Schedule 13G/A, indicates that certain funds managed by Renaissance Technologies LLC are entitled to receive dividends and proceeds from the sale of these securities.
Trading Systems Reacting to (UTMD) Volatility
This article analyzes the volatility of Utah Medical Products Inc. (NASDAQ: UTMD), highlighting a strong overweight bias across all sentiment horizons. It details three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, providing entry and exit points, targets, and stop losses. The analysis points to an exceptional 29.2:1 risk-reward setup for the stock.
UTAH MEDICAL PRODUCTS INC 1H 2026: Revenue $8.53M, EPS $0.84— 10-Q Summary
Utah Medical Products Inc. (UTMD) reported a decline in first-half 2026 financial results, with consolidated revenue falling to $8.53 million and diluted EPS to $0.84 compared to the prior year. This downturn was primarily attributed to the loss of two major customers, slower OEM wins, and reduced international sales. Despite these challenges, domestic sales of Filshie Clip grew, and the company increased inventories and maintained staffing for future product production, though litigation expenses are expected to impact 2026 legal costs.
Utah Medical Products 2Q FY26 net income falls 11.9% to USD 2.69 million; net sales drop 14.3% to USD 8.53 million
Utah Medical Products reported a significant decline in its second-quarter FY26 financial results, with net income falling 11.9% to USD 2.69 million and net sales dropping 14.3% to USD 8.53 million. The company attributed the sales decline to the absence of sales to two major customers and projected a 10%-13% decrease in full-year 2026 net sales due to slower-than-expected biopharma OEM customer sales. Operating income and gross profit also saw reductions, with operating margin narrowing by 1 percentage point and gross margin tightening by 0.4 percentage point due to tariffs.
Utah Medical Products Inc (UTMD) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article from TradingKey provides an earnings forecast for Utah Medical Products Inc (UTMD), focusing on future EPS and revenue growth estimates. It includes a snapshot of the company's current stock performance, market capitalization, and P/E ratio, alongside a list of peer companies for comparison. The content indicates an update on August 8, 2026, for financial forecasting, including EPS, Revenue, Net Profit, and EBIT.
Utah Medical Products raises quarterly dividend 1.6%
Utah Medical Products Inc. (Nasdaq:UTMD) has announced a 1.6% increase in its quarterly cash dividend, bringing it to $0.31 per share. The dividend is payable on October 5, 2026, to shareholders recorded by September 17, 2026. The company specializes in developing, manufacturing, and marketing disposable and reusable medical devices for women's and babies' healthcare.
Utah Medical Products, Inc. announces Quarterly dividend, payable on October 05, 2026
Utah Medical Products, Inc. has announced a quarterly dividend of $0.3100 per share. This dividend is payable on October 5, 2026, with an ex-date and record date set for September 17, 2026. The company specializes in developing, manufacturing, and marketing a wide range of disposable and reusable specialty medical devices, particularly for women's healthcare.
Utah Medical Products, Inc. Announces Quarterly Dividend of $0.31 (NASDAQ:UTMD)
Utah Medical Products, Inc. (NASDAQ:UTMD) declared a quarterly dividend of $0.31 per share, payable on October 5th to shareholders of record on September 17th. This dividend represents a 1.7% annualized yield, and the company has consistently increased its dividend for the past three years. Despite a slight dip in stock price, UTMD maintains a market capitalization of $229.91 million and institutional investors hold approximately 69.6% of its shares.
Utah Medical sets 31-cent payment for shareholders on Oct. 5
Utah Medical Products (Nasdaq: UTMD) announced that its Board of Directors has approved a quarterly cash dividend of $0.31 per share of common stock. This dividend, representing a 1.6% increase over the previous year's dividend for the same quarter, is payable on October 5, 2026, to shareholders of record as of September 17, 2026. The company specializes in developing, manufacturing, and marketing medical devices for women and babies.
Utah Medical Products raises quarterly dividend 1.6% By Investing.com
Utah Medical Products Inc. (NASDAQ:UTMD) has announced a quarterly cash dividend of $0.31 per share of common stock, representing a 1.6% increase from the previous year's dividend. The dividend will be payable on October 5, 2026, to shareholders of record as of September 17, 2026. The company specializes in developing, manufacturing, and marketing disposable and reusable specialty medical devices, particularly for women's and babies' healthcare.
How Utah Medical Products Inc. (UTMD) Affects Rotational Strategy Timing
This article from Stock Traders Daily analyzes Utah Medical Products Inc. (UTMD) and its impact on rotational strategy timing. It highlights a near-term strong sentiment possibly influencing mid-term neutrality and a long-term positive bias, noting a mid-channel oscillation pattern. The analysis provides specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels.
Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses
Utah Medical Products (UTMD) reported a significant decline in Q2 2026 earnings and revenue, primarily due to the loss of two major customers, PendoTECH and a China-based distributor. Despite the sales headwinds, the company maintained strong profitability with resilient margins and a robust balance sheet. Management has updated its full-year 2026 revenue outlook to a 10-13% decline, focusing on new product development and expanded customer relationships to mitigate losses.
Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses
Utah Medical Products, Inc. (UTMD) reported a significant year-over-year decline in Q2 2026 earnings and revenue, primarily due to the loss of two major customers. Diluted EPS decreased by 10.1% and revenues fell by 14.3%, although the company maintained solid profitability with resilient margins despite higher litigation expenses. Management has revised its full-year 2026 revenue outlook to a 10-13% decline, as new product sales have progressed slower than anticipated.
Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses
Utah Medical Products (UTMD) reported a significant decline in Q2 2026 earnings and revenue, primarily due to the loss of two major customers. Diluted EPS dropped by 10.1% and revenues fell by 14.3% year-over-year, leading the company to lower its full-year revenue outlook. Despite the sales challenges, UTMD maintained a strong balance sheet and solid profitability margins.
Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses
Utah Medical Products, Inc. (UTMD) reported a decline in Q2 2026 diluted EPS by 10.1% and revenues by 14.3% year-over-year, primarily due to the loss of sales from two major customers, PendoTECH and a China-based distributor. Despite the revenue decline, the company maintained strong profitability with a robust balance sheet and is focusing on new products and customer relationships to offset lost revenue, although the recovery is slower than anticipated. Management updated its full-year 2026 revenue outlook to a 10-13% decline compared to 2025.
Utah Medical's Q2 Earnings Down Y/Y Due to Customer Losses
Utah Medical Products (UTMD) reported a significant decline in Q2 2026 earnings and revenue, primarily due to the loss of two major customers, PendoTECH and a China-based distributor. Diluted EPS decreased by 10.1% and revenues fell by 14.3% year-over-year. Despite the sales decline, the company maintained resilient margins and a strong balance sheet, but has revised its full-year 2026 revenue outlook downwards.
Utah Medical Products Inc (UTMD) Valuation: PE, PB & Fair Value Analysis
Utah Medical Products Inc (UTMD) has a current valuation score of 8.45, placing it 93rd out of 199 companies in the Healthcare Equipment & Supplies industry. Its P/E ratio is 20.98, which is slightly below its recent high but significantly above its recent low. The company has not yet disclosed relevant data for P/B, P/S, and P/CF ratios.
Utah Medical Products Inc (UTMD) Cash Flow
This article provides a detailed cash flow statement for Utah Medical Products Inc (UTMD), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures in millions, showing year-over-year changes and absolute values for various cash flow components. The page also includes an FAQ section explaining key cash flow concepts and UTMD's specific figures for operating cash flow, capital expenditures, and free cash flow in recent periods.
UTMD|Utah Medical Products Inc|Price:69.000|Chg%:+1.860
This article provides a comprehensive stock analysis of Utah Medical Products Inc (UTMD) by TradingKey, highlighting its strong fundamentals and high growth potential. The company is considered fairly valued within the Healthcare Equipment & Supplies industry, despite recent weak stock market performance. The analysis also covers its key products, financial health, dividend history, institutional ownership, and risk assessment dimensions.
Utah Medical Products Inc (UTMD) Financial Health: Profitability & Balance Sheet Analysis
Utah Medical Products Inc (UTMD) has a robust financial score of 9.29, ranking 8th in the Healthcare Equipment & Supplies industry. Despite this strong overall financial health and high operating efficiency, the company experienced a year-over-year decrease of 10.18% in its latest quarterly revenue and a 14.37% decrease in net profit. The detailed financial analysis covers profitability, balance sheet, quality of earnings, operational efficiency, growth potential, and shareholder returns.
